<DOC>
	<DOCNO>NCT00200356</DOCNO>
	<brief_summary>This study randomize , Sodium Ozagrel ( Thromboxane A2 Synthase Inhibitor ) control study acute ischemic stroke . The primary endpoint rate patient modify Rankin Scale score 0-1 3 month .</brief_summary>
	<brief_title>Edaravone-Sodium Ozagrel Comparative Post-Marketing Study Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Ozagrel</mesh_term>
	<mesh_term>Phenylmethylpyrazolone</mesh_term>
	<mesh_term>Antipyrine</mesh_term>
	<criteria>1 . Patients receive drug treatment within 24 hour stroke onset 2 . Patients level consciousness 0 ( alert ) 3 ( unable recall name date birth ) accord Japan Coma Scale 3 . Patients motor dysfunction upper and/or low extremity 4 . Patients age 20 year old give informed consent 1 . Serum creatinine &gt; 1.5 mg/dL 2 . Embolic infarction 3 . Intracranial haemorrhage 4 . Large infarction severe consciousness 5 . Transient ischemic attack ( TIA ) 6 . A modified Rankin Scale score â‰¥2 stroke onset 7 . Patients receive drug treatment ( argatroban , urokinase , tissue plasminogen activator , heparin , warfarin sodium , aspirin , ticlopidine hydrochloride , cilostazol , edaravone sodium ozagrel ) stroke onset 8 . Patients receive surgical treatment intravascular treatment 9 . With severe complication ( cirrhosis , heart failure , etc . ) 10 . Treating malignant tumor 11 . Pregnant possibly pregnant woman , nurse mother 12 . History edaravone , sodium ozagrel ozagrel hydrochloride sensitivity 13 . Less 3 month since clinical trial postmarketing study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>